




PHARMACEUTICAL 2019

DYNAVAX TECHNOLOGIES CORP
Rank 272 of 363





PHARMACEUTICAL 2019

DYNAVAX TECHNOLOGIES CORP Rank 272 of 363



The relative strengths and weaknesses of DYNAVAX TECHNOLOGIES CORP are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of DYNAVAX TECHNOLOGIES CORP compared to the market average is the variable Other Liabilities, increasing the Economic Capital Ratio by 18% points. The greatest weakness of DYNAVAX TECHNOLOGIES CORP is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 109% points.

The company's Economic Capital Ratio, given in the ranking table, is -28%, being 65% points below the market average of 37%.

Input Variable	Value in 1000 USD
Assets, Current	174,364
Cost of Goods Sold	0
Intangible Assets	13,861
Liabilities, Current	38,033
Liabilities, Non-Current	109,786
Other Assets	5,595
Other Compr. Net Income	-1,134
Other Expenses	31,134
Other Liabilities	0
Other Net Income	3,758
Other Revenues	8,198
Property and Equipment	17,064
Research and Development	74,951
Selling, General and Administrative Expense	64,770

Output Variable	Value in 1000 USD
Assets	210,884
Liabilities	147,819
Expenses	170,855
Revenues	8,198
Stockholders Equity	63,065
Net Income	-158,899
Comprehensive Net Income	-159,466
Economic Capital Ratio	-28%